

## References M Trojano

Rosito S, Nicchia GP, Palazzo C, Lia A, Buccoliero C, Pisani F, Svelto M, **Trojano M**, Frigeri A. Supramolecular aggregation of aquaporin-4 is different in muscle and brain: correlation with tissue susceptibility in neuromyelitis optica. *J Cell Mol Med.* 2017 Oct 20. doi: 10.1111/jcmm.13401. [

Kalincik T, Manouchehrinia A, Sobisek L, Jokubaitis V, Spelman T, Horakova D, Havrdova E, **Trojano M**, Izquierdo G, Lugaresi A, Girard M, Prat A, Duquette P, Grammond P, Sola P, Hupperts R, Grand'Maison F, Pucci E, Boz C, Alroughani R, Van Pesch V, Lechner-Scott J, Terzi M, Bergamaschi R, Iuliano G, Granella F, Spitaleri D, Shaygannejad V, Oreja-Guevara C, Slee M, Ampapa R, Verheul F, McCombe P, Olascoaga J, Amato MP, Vucic S, Hodgkinson S, Ramo-Tello C, Flechter S, Cristiano E, Rozsa C, Moore F, Luis Sanchez-Menoyo J, Laura Saladino M, Barnett M, Hillert J, Butzkueven H; MSBase Study Group. Towards personalized therapy for multiple sclerosis: prediction of individual treatment response. *Brain.* 2017 Sep 1;140(9):2426-2443.

Kappos L, Butzkueven H, Wiendl H, Spelman T, Pellegrini F, Chen Y, Dong Q, Koendgen H, Belachew S, **Trojano M**; Tysabri® Observational Program (TOP) Investigators. Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study. *Mult Scler.* 2017 May

Tortorella C, Direnzo V, Ruggieri M, Zoccolella S, Mastrapasqua M, D'Onghia M, Paolicelli D, Cuonzo FD, Gasperini C, **Trojano M**. Cerebrospinal fluid neurofilament light levels mark grey matter volume in clinically isolated syndrome suggestive of multiple sclerosis. *Mult Scler.* 2017 May

Iaffaldano P, Simone M, Lucisano G, Ghezzi A, Coniglio G, Brescia Morra V, Salemi G, Patti F, Lugaresi A, Izquierdo G, Bergamaschi R, Cabrera-Gomez JA, Pozzilli C, Millefiorini E, Alroughani R, Boz C, Pucci E, Zimatore GB, Sola P, Lus G, Maimone D, Avolio C, Cocco E, Sajedi SA, Costantino G, Duquette P, Shaygannejad V, Petersen T, Fernández Bolaños R, Paolicelli D, Tortorella C, Spelman T, Margari L, Amato MP, Comi G, Butzkueven H, **Trojano M**; Italian iMedWeb Registry and the MSBase Registry. Prognostic indicators in pediatric clinically isolated syndrome. *Ann Neurol.* 2017 May;81(5):729-739.

Signori A, Izquierdo G, Lugaresi A, Hupperts R, Grand'Maison F, Sola P, Horakova D, Havrdova E, Prat A, Girard M, Duquette P, Boz C, Grammond P, Terzi M, Singhal B, Alroughani R, Petersen T, Ramo C, Oreja-Guevara C, Spitaleri D, Shaygannejad V, Butzkueven H, Kalincik T, Jokubaitis V, Slee M, Fernandez Bolaños R, Sanchez-Menoyo JL, Pucci E, Granella F, Lechner-Scott J, Iuliano G, Hughes S, Bergamaschi R, Taylor B, Verheul F, Edite Rio M, Amato MP, Sajedi SA, Majdinasab N, Van Pesch V, Sormani MP, **Trojano M**. Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis. *Mult Scler.* 2017 Apr

**Trojano M**, Tintore M, Montalban X, Hillert J, Kalincik T, Iaffaldano P, Spelman T, Sormani MP, Butzkueven H. Treatment decisions in multiple sclerosis - insights from real-world observational studies. *Nat Rev Neurol.* 2017 Feb;13(2):105-118.

Kalincik T, Brown JW, Robertson N, Willis M, Scolding N, Rice CM, Wilkins A, Pearson O, Ziemssen T, Hutchinson M, McGuigan C, Jokubaitis V, Spelman T, Horakova D, Havrdova E, **Trojano M**, Izquierdo G, Lugaresi A, Prat A, Girard M, Duquette P, Grammond P, Alroughani R, Pucci E, Sola P, Hupperts R, Lechner-Scott J, Terzi M, Van Pesch V, Rozsa C, Grand'Maison F, Boz C, Granella F, Slee M, Spitaleri D, Olascoaga J, Bergamaschi R, Verheul F, Vucic S, McCombe P, Hodgkinson S, Sanchez-Menoyo JL, Ampapa R, Simo M, Csepany T, Ramo C, Cristiano E, Barnett M, Butzkueven H, Coles A; MSBase Study Group. Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study. *Lancet Neurol.* 2017 Apr;16(4):271-281.

De Bellis M, Pisani F, Mola MG, Rosito S, Simone L, Buccoliero C, **Trojano M**, Nicchia GP, Svelto M, Frigeri A. Translational readthrough generates new astrocyte AQP4 isoforms that modulate supramolecular clustering, glial endfeet localization, and water transport. *Glia*. 2017 May;65(5):790-803. doi: 10.1002/glia.23126. Epub 2017 Feb 16. PubMed PMID: 28206694.

Paolicelli D, Manni A, D'Onghia M, Drenzo V, Iaffaldano P, Zoccolella S, Di Lecce V, Tortorella C, Specchia G, **Trojano M**. Lymphocyte subsets as biomarkers of therapeutic response in Fingolimod treated Relapsing Multiple Sclerosis patients. *J Neuroimmunol*. 2017 Feb 15;303:75-80.

Iaffaldano P, Viterbo RG, **Trojano M**. Natalizumab discontinuation is associated with a rebound of cognitive impairment in multiple sclerosis patients. *J Neurol*. 2016 Jun 3.

Iaffaldano P, Lucisano G, Pozzilli C, Brescia Morra V, Ghezzi A, Millefiorini E, Patti F, Lugaresi A, Zimatore GB, Marrosu MG, Amato MP, Bertolotto A, Bergamaschi R, Granella F, Coniglio G, Tedeschi G, Sola P, Lus G, Ferrò MT, Iuliano G, Corea F, Protti A, Cavalla P, Guareschi A, Rodegher M, Paolicelli D, Tortorella C, Lepore V, Prosperini L, Sacc<sup>†</sup> F, Baroncini D, Comi G, **Trojano M**; Italian iMed-Web database. Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis. *Brain*. 2015 Nov;138(Pt 11):3275-86.

Jokubaitis VG, Spelman T, Kalincik T, Lorscheider J, Havrdova E, Horakova D, Duquette P, Girard M, Prat A, Izquierdo G, Grammond P, Van Pesch V, Pucci E, Grand'Maison F, Hupperts R, Granella F, Sola P, Bergamaschi R, Iuliano G, Spitaleri D, Boz C, Hodgkinson S, Olascoaga J, Verheul F, McCombe P, Petersen T, Rozsa C, Lechner-Scott J, Laura Saladino M, Farina D, Iaffaldano P, Paolicelli D, Butzkueven H, Lugaresi A, **Trojano M**; MSBase Study Group. Predictors of long-term disability accrual in relapse-onset multiple sclerosis. *Ann Neurol*. 2016 May 4.

Jokubaitis VG, Spelman T, Kalincik T, Izquierdo G, Grand'Maison F, Duquette P, Girard M, Lugaresi A, Grammond P, Hupperts R, Cabrera-Gomez J, Oreja-Guevara C, Boz C, Giuliani G, Fernandez-Bola<sup>±</sup>os R, Iuliano G, Lechner-Scott J, Verheul F, van Pesch V, Petkovska-Boskova T, Fiol M, Moore F, Cristiano E, Alroughani R, Bergamaschi R, Barnett M, Slee M, Vella N, Herbert J, Shaw C, Saladino ML, Amato MP, Liew D, Paolicelli D, Butzkueven H, **Trojano M**. Predictors of disability worsening in clinically isolated syndrome. *Ann Clin Transl Neurol*. 2015 May;2(5):479-91.

Bergamaschi R, Montomoli C, Mallucci G, Lugaresi A, Izquierdo G, Grand'Maison F, Duquette P, Shaygannejad V, Alroughani R, Grammond P, Boz C, Iuliano G, Zwanikken C, Petersen T, Lechner-Scott J, Hupperts R, Butzkueven H, Pucci E, Oreja-Guevara C, Cristiano E, Pia Amato MP, Havrdova E, Fernandez-Bolanos R, Spelman T, **Trojano M**. BREMSO: a simple score to predict early the natural course of multiple sclerosis. *Eur J Neurol*. 2015 Jun;22(6):981-9.

Kalincik T, Horakova D, Spelman T, Jokubaitis V, **Trojano M**, Lugaresi A, Izquierdo G, Rozsa C, Grammond P, Alroughani R, Duquette P, Girard M, Pucci E, Lechner-Scott J, Slee M, Fernandez-Bolanos R, Grand'Maison F, Hupperts R, Verheul F, Hodgkinson S, Oreja-Guevara C, Spitaleri D, Barnett M, Terzi M, Bergamaschi R, McCombe P, Sanchez-Menoyo J, Simo M, Csepany T, Rum G, Boz C, Havrdova E, Butzkueven H; MSBase Study Group. Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis. *Ann Neurol*. 2015 Mar;77(3):425-35.

Marrie RA, Reider N, Cohen J, Stuve O, Sorensen PS, Cutter G, Reingold SC, **Trojano M**. A systematic review of the incidence and prevalence of autoimmune disease in multiple sclerosis. *Mult Scler*. 2015 Mar;21(3):282-93.

**Trojano M**, Tortorella C. MS and related disorders: looking for markers of phenotypes. *Lancet Neurol*. 2015 Jan;14(1):11-3.